OpGen to Provide Business Update and Financial Results for the First Quarter 2022 on May 12th at 4:30 p.m. Eastern Time
April 28 2022 - 6:30AM
OpGen, Inc. (NASDAQ: OPGN) (“OpGen” or “the Company”) announced
today that the Company will provide a business update and report
its first quarter 2022 financial results after the close of the
U.S. financial markets on Thursday, May 12th, 2022. OpGen’s
management team will host a live conference call and audio webcast
at 4:30 p.m. Eastern Time to discuss the Company’s financial
results and provide an update on business activities.
Conference Call Details |
|
U.S. Dial-in Number: |
1-877-704-4453 |
International Dial-in Number: |
1-201-389-0920 |
Webcast: |
https://services.choruscall.com/mediaframe/webcast.html?webcastid=n37Dadqy |
Conference ID: |
13729189 |
Replay Details |
|
U.S. Dial-in Number: |
1-844-512-2921 |
International Dial-in Number: |
1-412-317-6671 |
Replay PIN: |
13729189 |
Following the conclusion of the conference call,
a replay will be available through May 26th, 2022. The live,
listen-only webcast of the conference call may also be accessed by
visiting the Investors section of the Company’s website at
www.opgen.com. A replay of the webcast will be available following
the conclusion of the call and will be archived on the Company’s
website under Financials & Filings.
About OpGen, Inc.
OpGen, Inc. (Rockville, MD, USA) is a precision
medicine company harnessing the power of molecular diagnostics and
bioinformatics to help combat infectious disease. Along with our
subsidiaries, Curetis GmbH and Ares Genetics GmbH, we are
developing and commercializing molecular microbiology solutions
helping to guide clinicians with more rapid and actionable
information about life threatening infections to improve patient
outcomes, and decrease the spread of infections caused by
multidrug-resistant microorganisms, or MDROs. OpGen’s product
portfolio includes Unyvero®, Acuitas® AMR Gene Panel and the ARES
Technology Platform including ARESdb®, using NGS technology and
AI-powered bioinformatics solutions for antibiotic response
prediction.
For more information, please visit www.opgen.com.
OpGen:Oliver SchachtPresident and
CEOInvestorRelations@opgen.com
OpGen Press Contact:Matthew Bretzius FischTank
Marketing and PRmatt@fischtankpr.com
OpGen Investor Contact:Alyssa FactorEdison
Group afactor@edisongroup.com
OpGen (NASDAQ:OPGN)
Historical Stock Chart
From Sep 2024 to Oct 2024
OpGen (NASDAQ:OPGN)
Historical Stock Chart
From Oct 2023 to Oct 2024